# Analyzing-public-companies-in-the-life-sciences-and-designing-an-investment-portfolio
Our algorithm clustered biotech companies based on trading data only, as opposed to information required by due diligence like therapeutic pipeline, stage of clinical trials, the competitive landscape, etc
